DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
Besides Wall Street's top-and-bottom-line estimates for DexCom (DXCM), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
DexCom: Delivering Consistent Growth
DexCom focuses on continuous glucose monitoring systems, with a strong market position and global reach. Q1 results showed 13% revenue growth, beating expectations, though earnings were slightly below consensus. Analysts remain bullish, with most issuing Buy ratings and price targets ranging from $87 to $110 per share.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Amarin (AMRN) have performed compared to their sector so far this year.
DexCom (DXCM) Upgraded to Strong Buy: Here's What You Should Know
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
Here is how DexCom (DXCM) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
3 Reasons Growth Investors Will Love DexCom (DXCM)
DexCom (DXCM) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why DexCom (DXCM) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DXCM's Access Gains and Operational Strength Offset Margin Pressures
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DXCM continues to raise investor optimism due to its strong product portfolio.
Top Health & Fitness Stocks to Buy for the Wellness Boom
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit.
